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LETTER TO THE EDITORSuccessful Hematopoietic
Stem Cell Transplantation
from an HLA-Identical Sibling
in a Patient with Aplastic
Anemia after HLA-
Haploidentical Living-Related
Liver Transplantation for
Fulminant Hepatitis
We report a case of hematopoietic stem cell trans-
plantation (HSCT) from an HLA-identical brother
with no signs of hepatic graft-versus-host disease
(GVHD), hepatic rejection, or hepatic sinusoidal ob-
struction syndrome (SOS) in a patient with severe
aplastic anemia (SAA) who had previously undergone
living-related liver transplantation (LRLT) from an
HLA-haploidentical sister for fulminant hepatitis. An
18-year-old female was transferred to our institution
with hepatic encephalopathy. On admission, her labo-
ratory data were as follows: total bilirubin, 204 mmol/
L; prothrombin time-INR, 2.26; white blood cell
count, 5.7  109/L; hemoglobin, 109 g/L; platelet
count, 90  109/L. Markers for viral hepatitis were
negative. Three days after admission, the patient un-
derwent an auxiliary partial orthotopic LRLT using
a left liver graft from her ABO-matched, HLA-haploi-
dentical sister. Histological examination demonstrated
hepatic necrosis, but the patient exhibited no signs ofTable I. HSCT in patients with aplastic anemia post-liver transplan
Patient and Reference
Liver Transplant
Donor/Source HSCT Source HSCT Do
6.5-year-old male1 (Cadaveric) Marrow HLA-matched
29-year-old male2 (Cadaveric) Marrow HLA-matched
2.5-year-old male3 (Cadaveric) Marrow HLA-matched
8-year-old male4 (Cadaveric) Marrow HLA-matched
6-year-old male5 Living-related
HLA-1-locus
mismatched father*
Cord blood
and marrow
HLA-matched
1.6-year-old male6 Living-related
HLA- haploidentical
father
Cord blood Self
19-year-old female
(present case)
Living-related
HLA-haploidentical
sister
Marrow HLA-matchedb
MTX indicates methotrexate; PSL, prednisolone; HSCT, hematopoietic stem ce
no data; Cy, cyclophosphamide; TLI, total lymphoid irradiation; SOS, sinusoida
*Serologic mismatch.chronic hepatic disease. Tacrolimus and methylpred-
nisolone were administered for rejection prophylaxis.
Progressive pancytopenia developed after trans-
plantation (absolute neutrophil count [ANC], 0.8 
109/L; hemoglobin, 58 g/L; platelet count, 37  109/
L on day 7). Bone marrow biopsy revealed hypoplastic
marrow with cellularity\10%. A diagnosis of hepati-
tis-associated SAA was assigned. Administration of
horse antithymocyte globulin (ATG) or rabbit ATG
together with cyclosporine A (CsA) and granulocyte
colony-stimulating factor (G-CSF) resulted in only
transient hematologic recovery (ANC . 1.0  109/L).
Evaluation of liver function by technetium-99m galac-
tosyl serum albumin (GSA) scintigraphy revealed nor-
mal liver function reserve (LHL15 5 0.935 [normal,
. 0.91]) with accumulation predominately in the right
lobe, suggesting native liver regeneration.
Given the patient’s status, we decided to perform
HSCT using bone marrow from her HLA-matched
brother. The conditioning regimen comprised cyclo-
phosphamide (Cy), 50 mg/kg/day for 5 days, and 7.5
Gy of total lymphoid irradiation (TLI). For HSCT,
the patient received 2.8  108 marrow mononuclear
cells/kg. Immunosuppression after transplantation
consisted of 3 doses of methotrexate (MTX; 10 mg/
kg on day 1 and 7 mg/kg on days 3 and 6), continuous
infusion of CsA (with a target blood level of 450 to 550
ng/mL), and methylprednisolone 2 mg/day. She
achieved an ANC. 0.5 109/L on day 14 after trans-
plantation. Full donor chimerism was confirmed by
XY fluorescein in situ hybridization (FISH) on day
28. The posttransplantation course was uneventful,
with no evidence of acute GVHD (aGVHD). Attation
nor
GVHD
Prophylaxis
Conditioning
Regimen
Acute
GVHD SOS EFS
sister CsA/MTX/PSL Cy/ATG - - 2 years
brother CyA/PSL CY/TLI Skin
grade I
- 1 year
sister CsA/MTX/PSL Cy/ATG - - 3 years
brother FK506/MTX/PSL Cy/ATG - - 1 year
sister CyA/MTX Cy/TLI - + 9 months
ND ATG/CsA/
PSL/G-CSF
ND - 3 years
rother CyA/MTX/PSL Cy/TLI - - 6 months
ll transplantation; FK506, tacrolimus; ATG, antithymocyte globulin; ND,
l obstruction syndrome; CsA, cyclosporine; EFS, event-free survival.
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lent health and free from any signs of chronic GVHD
or liver dysfunction on the basis of symptoms, labora-
tory data, computed tomography, and abdominal ul-
trasonography, on a daily regimen of CsA 200 mg
and methylprednisolone 2 mg.
To the best of our knowledge, 6 cases of HSCT for
SAA after liver transplantation have been reported pre-
viously (Table 1) [1-6]. Significantly, only 1 of these
patients underwent allogeneic HSCT for SAA; this pa-
tient had received a serologically one-locus-mis-
matched (in the graft-versus-host direction) liver
transplant from his father and a serologically identical
stem cell transplant from his sister [5]. The most sig-
nificant conclusion that can be drawn from the present
case is that allogeneic HSCT for a recipient of HLA-
haploidentical LRLT can be performed safely, at least
in conjunction with sufficient immunosuppression
therapy. We also report here the possible usefulness
of GSA scintigraphy before HSCT as a functional
evaluation of the recipient’s own liver, considering
that severe GVHD can impair the function of an
HLA-haploidentical liver graft.REFERENCES
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